New cancer drug RS-0139 tested in 16 patients
NCT ID NCT04261413
First seen Apr 01, 2026 · Last updated May 14, 2026 · Updated 6 times
Summary
This early-phase trial tested a new drug called RS-0139 in 16 adults with advanced solid tumors that had come back or spread. The main goal was to find the best dose and check for side effects. Researchers also looked at whether the drug could shrink tumors or slow cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abdurrahman Yurtaslan Ankara Onkoloji Eğitim ve Araştırma Hastanesi
Ankara, Turkey (Türkiye)
-
Koç University Hospital Phase I Center
Istanbul, Turkey (Türkiye)
Conditions
Explore the condition pages connected to this study.